Journal of Clinical Oncology
Articles in this Issue
Real-world (rw) study of the treatment journey following antibody-drug conjugate (ADC) initiation and overall survival (OS) in breast cancer (BC) in a US community setting.
e13089 Background: ADCs have transformed the BC treatment landscape by providing clinically meaningful improvements in pat...
Treatment-related changes in body composition during maximal androgen blockade (MAB) for metastatic hormone-sensitive prostate cancer (mHSPC).
e17097 Background: Androgen deprivation therapy (ADT) combined with an androgen receptor pathway inhibitors (ARPI) +/- doc...
Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.
2076 Background: Glioblastoma (GBM) is a poor-prognosis brain malignancy with median overall survival (mOS) of ~12-18 mont...
Endometrial cancer response to pro-EMT effects of type 2 diabetic exosomes.
e22617 Background: According to the International Diabetes Federation, over 151 million adults globally suffer from Type 2...
Systemic therapy for stage IV primary extramammary Paget disease: A systematic review of reported clinical outcomes.
e21564 Background: Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma with limited evidence guiding syst...
GLP-1 receptor agonist therapy and cancer risk and mortality in patients with moderate CKD: A national matched cohort study of 58,000 patients.
10583 Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been associated with reduced mortality in pat...
Beyond haematological control: Long-term renal outcomes of imatinib therapy in chronic myeloid leukaemia.
6581 Background: Imatinib has transformed outcomes in chronic myeloid leukaemia (CML), enabling long-term survival and dur...
Efficacy, safety, and immunogenicity of pertuzumab biosimilar versus reference pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer: A randomized, double-blind, multicenter, parallel group, phase III clinical trial.
1047 Background: Pertuzumab plus trastuzumab and docetaxel is a standard first-line treatment regimen for HER2-positive me...
FOLFIRINOX vs gem/pac in the elderly: Is the survival benefit worth the risk?
e16420 Background: FOLFIRINOX (FFX) is standard first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC) but is...
Diagnostic accuracy of circulating tumor DNA for post-remission surveillance in diffuse large B-cell lymphoma: A systematic review and meta-analysis.
7060 Background: Relapse after complete remission remains a major cause of treatment failure in Diffuse Large B-Cell Lymph...
Cost of cytokine release syndrome in patients treated with tarlatamab for extensive-stage small cell lung cancer based on first-line treatment.
e13554 Background: Tarlatamab is a second-line treatment for extensive-stage small cell lung cancer (SCLC) and has changed...
Insurance-related disparities in emergency department presentation among hospitalized colorectal cancer patients: A national analysis.
e15682 Background: Insurance status may influence how and when patients with colorectal cancer (CRC) access care, leading...
BRCA-P: Can denosumab reduce breast cancer risk in <i>BRCA1</i> mutation carriers?
TPS10630 Background: The likely ‘cell-of-origin’ that leads to breast cancer in BRCA1...
Efficacy and safety of anamorelin in patients with non–small cell lung cancer and cancer cachexia undergoing chemoimmunotherapy: A real-world prospective cohort study (SPIRAL-ANA).
8592 Background: The efficacy and safety of combining anamorelin with chemoimmunotherapy for non–small cell lung cancer (N...
Preferences among women for home-based self-sampling over clinic-based provider-collection for cervical cancer screening in the US.
e22572 Background: Self-sampling for human papillomavirus testing is an evidence-based strategy that can improve cervical...
Longitudinal assessment of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer (MBC) on treatment with CDK4/6 inhibitors.
e13064 Background: The detection and enumeration of circulating tumor cells (CTCs) in the peripheral blood is an independe...
Conditional survival in advanced melanoma treated with immune checkpoint inhibitors.
12108 Background: Immune checkpoint inhibitors (ICI) have improved survival in advanced melanoma, with some patients achie...
A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553).
6012 Background: A subset of salivary gland cancers (SGCs) express the androgen receptor (AR). A prior AR+ SGC trial with...
Treatment response and clinical outcomes of patients with triple negative invasive apocrine breast carcinoma.
e12727 Background: Invasive apocrine carcinoma (IAC) is a rare subtype of breast cancer that is classically triple negativ...
Impact of being aged 80 years and older on treatment decision-making: Discrepancies in cancer care and associated outcomes.
e13770 Background: Patients aged ≥80 years old (yo) account for ~14% of lung cancer (LC) diagnoses, yet are often underrep...
Oncogenic EGFR amplification in EGFR-mutated NSCLC: EGFR subtype–dependent association with benefit from first-line osimertinib.
e20534 Background: De novo oncogenic amplification, including EGFR and...
Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106).
566 Background: Endocrine therapy (ET) resistance (ETR) remains a primary challenge in ER+ breast cancer. Analyzing pretre...
A systematic review and meta-analysis of cardioprotective effects of SGLT2 inhibitors compared to non-SGLT2 inhibitors in patients receiving cardiotoxic chemotherapy.
e24037 Background: As anticancer therapies advanced over the past decades, cancer-related mortality has decreased, but the...
Structured oncologist appraisal of AI-generated clinical literature summaries.
e23296 Background: In alignment with the American Society of Clinical Oncology’s guiding principles for responsible use of...
Phase II study of izalontamab (SI-B001) in combination with paclitaxel or docetaxel in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
6019 Background: Izalontamab is a bispecific antibody targeting EGFR and HER3. Here we present safety and efficacy results...